Mutant TP53 interacts with BCAR1 to contribute to cancer cell invasion

Area of Science:

• Oncology
• Molecular Biology
• Cancer Research

Background:

• Mutant TP53 (tumor protein 53) proteins exhibit gain-of-function properties, promoting cancer metastasis through interactions with other proteins.
• The precise mechanisms underlying TP53 gain-of-function mutations in cancer progression remain incompletely elucidated.

Purpose of the Study:

• To identify novel binding partners of the TP53^R273H mutant, a common driver in human cancers.
• To investigate the functional consequences of the interaction between TP53^R273H and its novel binding partner, breast cancer anti-estrogen resistance 1 (BCAR1).

Main Methods:

• Immunoprecipitation and proximity ligation assays were employed to identify and validate TP53^R273H-BCAR1 binding.
• Transwell invasion assays were utilized to assess the functional impact of the TP53^R273H-BCAR1 interaction on cancer cell invasion.
• Public patient databases were analyzed to correlate TP53 status and BCAR1 expression with clinical outcomes.

Main Results:

• A novel interaction between TP53^R273H and BCAR1 was discovered.
• BCAR1 nuclear translocation and binding to TP53^R273H were found to be dependent on SRC family kinases (SFKs).
• TP53^R273H expression, but not a BCAR1 binding-deficient mutant, significantly promoted cancer cell invasion, and high BCAR1 expression correlated with poorer prognosis in mutant TP53 patients.

Conclusions:

• The interaction between TP53^R273H and BCAR1 is a key driver of enhanced cancer cell invasion.
• Disrupting the TP53^R273H-BCAR1 binding represents a potential therapeutic strategy for cancers harboring the TP53^R273H mutation.